Technical Analysis for PLRX - Pliant Therapeutics, Inc.

Grade Last Price % Change Price Change
C 32.61 -2.32% -0.78
PLRX closed down 2.32 percent on Monday, February 6, 2023, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Feb 27
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Wide Bands Range Expansion -2.32%
Overbought Stochastic Strength -2.32%
Down 3 Days in a Row Weakness -2.32%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 3 hours ago
Down 1% about 3 hours ago
Possible NR7 about 4 hours ago
Possible Inside Day about 4 hours ago
60 Minute Opening Range Breakdown about 5 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Pliant Therapeutics, Inc. Description

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Alcohol Steatohepatitis Hepatitis Non Alcoholic Fatty Liver Disease Idiopathic Pulmonary Fibrosis Orphan Drug Pulmonary Fibrosis Hepatology Fibrosis Drug Design Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Fibrosis Liver Fibrosis Muscular Dystrophies Primary Sclerosing Cholangitis Integrin

Is PLRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 36.64
52 Week Low 3.965
Average Volume 885,789
200-Day Moving Average 17.45
50-Day Moving Average 22.63
20-Day Moving Average 28.47
10-Day Moving Average 34.27
Average True Range 2.00
RSI 67.53
ADX 46.89
+DI 39.17
-DI 12.49
Chandelier Exit (Long, 3 ATRs) 30.63
Chandelier Exit (Short, 3 ATRs) 24.19
Upper Bollinger Bands 40.87
Lower Bollinger Band 16.06
Percent B (%b) 0.67
BandWidth 87.17
MACD Line 3.71
MACD Signal Line 3.51
MACD Histogram 0.2081
Fundamentals Value
Market Cap 1.16 Billion
Num Shares 35.5 Million
EPS 0.27
Price-to-Earnings (P/E) Ratio 119.71
Price-to-Sales 10.62
Price-to-Book 3.34
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.88
Resistance 3 (R3) 35.09 34.54 34.50
Resistance 2 (R2) 34.54 33.97 34.44 34.37
Resistance 1 (R1) 33.58 33.61 33.31 33.37 34.25
Pivot Point 33.03 33.03 32.90 32.93 33.03
Support 1 (S1) 32.07 32.46 31.80 31.86 30.97
Support 2 (S2) 31.52 32.10 31.42 30.85
Support 3 (S3) 30.56 31.52 30.72
Support 4 (S4) 30.35